RESUMO
Objective To investigate the relationship between frailty and serum biomarkers in the elderly. Methods A total of 371 elderly individuals aged 60 years and above with complete medical data were recruited during health examinations. Frailty phenotype assessment and comprehensive geriatric assessment were conducted.Serum levels of interleukin-6 (IL-6 ) ,high sensitivity C-reactive protein(hs-CRP) ,tumor necrosis factor-α(TNF-α) ,homocysteine(Hcy) ,insulin-like growth factor-1(IGF-1) ,25-hydroxyvitamin D[25(OH)D] ,folic acid and vitamin B12(VitB12) were detected by enzyme-linked immunosorbent assays ( ELISA ) and chemiluminescence immunoassays. Associations between frailty and the above factors were analyzed. Results Serum levels of IL-6 ,TNF-α ,Hcy and IGF-1 were significantly elevated along with progressive increase in frailty severity(all P＜0.05).There were a downward trend in serum 25(OH)D levels and an upward trend in serum hs-CRP ,folic acid and VitB12 levels as frailty severity increased ,but the changes did not amount to any statistical significance(all P＞0.05).Logistic regression analysis showed that ,after adjusting for age ,gender ,body mass index (BMI)and some clinical aspects (hearing loss ,urinary incontinence ,pain ,malnutrition ,cognitive dysfunction ,decreased activities of daily living ,depression , insomnia ,and anemia) ,serum levels of IL-6(OR=1.012 ,95% CI=1.005-2.041 ,P=0.033) ,IGF-1 (OR= 1.017 ,95% CI = 1.011-1.118 ,P= 0.021)and Hcy (OR= 1.007 ,95% CI :1.002-1.073 ,P=0.047)were significantly associated with frailty status. Conclusions Serum levels of IL-6 ,Hcy and IGF-1 are related to frailty status and may be used as potential biomarkers for the assessment of frailty in older adults.
RESUMO
Objective To observe the effect of levosimendan in the treatment of pulmonary heart disease patients with heart failure.Methods 60 patients were randomly divided into treatment group and control group.The treatment group used levosimendan.The control group used digitalis.We observed the NT -PROBNP, echocardio-graphic and clinical efficacy.Adverse drug reactions were observed too.Results The significantly effect of the treat-ment group was 22 cases(73%),and effective was 8 cases (27%).The significant effect of the control group was 14 cases (43%),and effective was 16 cases (57%).The levels of NT-PROBNP and pulmonary artery pressure in the treatment group were ( 416 ±311 ) pg/mL, ( 51 ±9 ) mmHg after 1 month treatment, which in the control group were (1 516 ±250) ng/mL,(57 ±10) mmHg.The efficacy of the treatment group was better than the control group (χ2 =4.44,P<0.05),the levels of NT-PROBNP and pulmonary artery pressure were lower(t=15.10,2.44,all P<0.05).Conclusion The levosimendan had effects on the pulmonary heart disease patients with heart failure.